In a patient with known interstitial lung disease (ILD) not currently flaring, who has an elevated brain natriuretic peptide (BNP), progressive dyspnea, and moderate pulmonary hypertension (PH) on transthoracic echocardiography (TTE), what are the differential diagnoses and what should be the next diagnostic and therapeutic steps?

Differential Diagnosis and Next Steps

In a patient with known ILD (not flaring), elevated BNP, progressive dyspnea, and moderate pulmonary hypertension on echo, you must immediately pursue right heart catheterization (RHC) to confirm true pulmonary hypertension and distinguish between Group 3 PH (due to ILD itself) versus "out-of-proportion" PH that may warrant specific therapy. 1, 2

Key Differential Diagnoses

Your primary considerations are:

1. Pulmonary hypertension due to ILD (Group 3 PH) - Most likely given the known ILD, though typically mild
2. "Out-of-proportion" PH - When PH severity exceeds what would be expected from the degree of lung disease alone 1, 2
3. Chronic thromboembolic pulmonary hypertension (CTEPH) - Must be excluded, especially with progressive symptoms 3
4. Left heart disease (Group 2 PH) - Elevated BNP raises concern for LV dysfunction or diastolic dysfunction 1, 4
5. Pulmonary arterial hypertension (PAH) - Consider if ILD is associated with connective tissue disease 5
6. Acute exacerbation of ILD - Though you state "not in flare," progressive symptoms warrant reconsideration

Critical Diagnostic Algorithm

Step 1: Confirm the Diagnosis of PH

Echocardiography alone is insufficient for treatment decisions 1, 4. While your echo shows "moderate PH," studies demonstrate that:

• Echo has high positive predictive value (86%) when TR velocity >3.4 m/s 6
• However, echo misclassifies 40% of ILD patients as "low probability" when PH is actually present 6
• Echo cannot distinguish between precapillary and postcapillary PH 7

You must proceed to RHC to:

• Confirm PH (mPAP ≥25 mmHg, PVR ≥3 Wood units) 3, 1
• Measure pulmonary capillary wedge pressure (PCWP) to exclude left heart disease (PCWP ≤15 mmHg for precapillary PH) 3, 1
• Quantify severity for prognostication and treatment decisions 4

Step 2: Exclude CTEPH

Before attributing PH solely to ILD, you must exclude CTEPH 3:

• Obtain ventilation-perfusion (V/Q) scan - This is critical as CT angiography can appear relatively normal in CTEPH despite significant V/Q abnormalities 3
• If V/Q scan shows segmental or larger perfusion defects, proceed to pulmonary angiography
• Confirm therapeutic anticoagulation for ≥3 months if thromboembolic disease is present 3

Step 3: Assess for Left Heart Disease

Given the elevated BNP:

• RHC will measure PCWP (must be ≤15 mmHg to exclude Group 2 PH) 3, 1
• Consider echocardiographic assessment of LV systolic and diastolic function 4
• Note: Severe RV dilation can cause interventricular dependence and elevate PCWP despite normal LV function 3

Step 4: Characterize "Out-of-Proportion" PH

Look for these red flags suggesting PH severity exceeds ILD severity 1, 2, 8, 9:

• DLCO <45% predicted 4, 10
• FVC/DLCO ratio >1.6 11
• Severe hypoxemia with only mild-moderate airway obstruction 2
• Pulmonary artery diameter >29 mm on CT 11
• mPAP >35-45 mmHg on RHC 2

Step 5: Additional Diagnostic Testing

Immediately obtain:

• Repeat high-resolution CT chest - Assess for ILD progression, exclude new processes, measure PA diameter 1, 12, 5
• Pulmonary function tests (PFTs) - Spirometry, lung volumes (TLC), and DLCO to establish baseline and assess severity 1, 12, 5
  • Serial decline in DLCO by ~5% per year warrants RHC 10
• 6-minute walk test with oximetry - Assess functional capacity and desaturation 13
• Arterial blood gas - Evaluate for hypoxemia, hypercapnia 1, 4

Consider:

• Autoimmune serologies if not previously done - CTD-ILD has different implications for PH management 5
• NT-proBNP or serial BNP - Rising levels should prompt echocardiography and RHC evaluation 10, 13
• Bronchoscopy with BAL - Only if infection or alternative diagnosis suspected 14

Management Priorities

Before RHC Results:

1. Optimize oxygenation - Long-term oxygen therapy if hypoxemic (PaO₂ <55-60 mmHg) 1
2. Treat underlying ILD - Ensure optimal immunosuppression/antifibrotic therapy as appropriate 1
3. Avoid empiric vasodilators - Can worsen V/Q mismatch and hypoxemia 1, 2

After RHC Confirmation:

• If Group 3 PH (due to ILD): No PAH-specific therapy recommended outside clinical trials 1, 2
• If "out-of-proportion" PH: Consider enrollment in clinical trials; inhaled treprostinil is the only FDA-approved therapy for PH-ILD 8, 9
• If CTEPH: Anticoagulation and referral for pulmonary thromboendarterectomy evaluation 3
• Refer for lung transplant evaluation if appropriate - PH is a poor prognostic factor in ILD 1, 5

Critical Pitfalls to Avoid

1. Do not rely on echo alone - 40% misclassification rate in ILD patients 6
2. Do not skip V/Q scan - CT can miss CTEPH 3
3. Do not start PAH-specific drugs empirically - Trials of epoprostenol and bosentan in heart failure were terminated early due to increased adverse events 1
4. Do not assume symptoms are "just ILD" - Progressive dyspnea with elevated BNP demands PH evaluation 10, 13
5. Do not delay RHC - Early diagnosis impacts transplant candidacy and clinical trial eligibility 13